• OM-MSCs Mitigate Golgi Stress via PEDF-PI3K/Akt/mTOR After S

  2026-05-07

  This study elucidates how olfactory mucosa mesenchymal stem cells (OM-MSCs) reduce Golgi apparatus (GA) stress responses following cerebral ischemia/reperfusion injury (IRI), primarily through the PEDF-PI3K/Akt/mTOR pathway. The findings provide mechanistic insight into stem cell-based neuroprotection and highlight mTOR signaling as a therapeutic axis in ischemic stroke models.

• E. coli Uracil-DNA Glycosylase (UDG): Lab Use and Protocols

  2026-05-06

  E. coli Uracil-DNA Glycosylase (UDG) efficiently removes uracil residues from DNA, helping prevent PCR carryover contamination and supporting DNA damage repair research. It is not suitable for RNA, short oligonucleotides (<6 bases), or any diagnostic or clinical applications.

• Merimepodib (VX-497): Strategic Leverage in Translational Re

  2026-05-06

  This thought-leadership article explores the mechanistic rationale, experimental validation, and translational strategy for deploying Merimepodib (VX-497) as a precision tool in cancer, immunology, and antiviral research. Grounded in recent findings on IMPDH-dependent guanine nucleotide biosynthesis, it provides actionable guidance for translational researchers and distinguishes itself by bridging metabolic insight with strategic workflow optimization.

• Plerixafor (AMD3100): Optimizing CXCR4 Axis Inhibition Workf

  2026-05-05

  Plerixafor (AMD3100) is the gold-standard small molecule for dissecting CXCL12/CXCR4 signaling, enabling high-fidelity cancer metastasis inhibition and hematopoietic stem cell mobilization research. This article delivers actionable protocols, troubleshooting insights, and an expert synthesis of emerging evidence to empower reproducible, translational results.

• Red Blood Cell Lysis Buffer: Enabling Advanced Hematology As

  2026-05-05

  Explore how Red Blood Cell Lysis Buffer empowers reliable erythrocyte removal while preserving nucleated cells for high-fidelity hematological and molecular research. This article delivers in-depth analysis, protocol guidance, and actionable insights beyond standard workflows.

• Technical Workflow: Hoechst 33342/PI Double Staining Kit (K2

  2026-05-04

  The Hoechst 33342/PI Double Staining Kit enables researchers to distinguish viable, apoptotic, and necrotic cells using fluorescence-based assessment of nuclear and membrane integrity. This kit is intended for basic research workflows and is not suitable for diagnostic or clinical use.

• Tiamulin (Thiamutilin): Reliable Solutions for Lab Assays

  2026-05-04

  This article presents data-driven strategies for overcoming core experimental challenges in cell viability, proliferation, and cytotoxicity assays using Tiamulin (Thiamutilin) (SKU BA1083). Scenario-based Q&As provide quantitative insights, validated protocols, and candid product selection guidance, helping researchers achieve reproducible outcomes with confidence.

• Firefly Luciferase mRNA: 5-moUTP Power for Robust Reporter A

  2026-05-03

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) empowers bioluminescent reporter workflows with enhanced stability, immune evasion, and superior translation. Its unique 5-moUTP modification and Cap 1 structure deliver reproducible results for both in vitro and in vivo gene regulation and imaging studies.

• SPRTN’s Dual Ubiquitin Binding Accelerates DNA-Protein Cross

  2026-05-02

  This study reveals how the SPRTN protease utilizes a distinct dual ubiquitin binding mode via its Ubiquitin interface of SprT Domain (USD) to specifically target and rapidly degrade polyubiquitinated DNA-protein crosslinks (DPCs). These findings clarify the molecular basis underlying SPRTN’s substrate specificity and highlight key mechanisms for maintaining genome stability.

• Patient-Derived 3D Spheroid Cultures Advance Prostate Cancer

  2026-05-02

  This study establishes and characterizes patient-derived 3D spheroid cultures as translational in vitro models for organ-confined prostate cancer. The model enables drug response testing and more faithfully recapitulates tumor heterogeneity, with implications for both mechanistic research and preclinical evaluation of androgen pathway inhibitors.

• CCR7–Notch1 Crosstalk Promotes Stemness in Mammary Cancer Ce

  2026-05-01

  Boyle et al. (2017) reveal a functional interplay between the chemokine receptor CCR7 and Notch1 signaling pathways, demonstrating their joint role in maintaining stem-like properties in mammary cancer cells. This mechanistic insight highlights potential therapeutic targets for limiting cancer recurrence and resistance in breast tumors.

• Griseofulvin as a Precision Tool for Aneugenicity Assays

  2026-04-30

  Explore the unique value of Griseofulvin as a microtubule associated inhibitor in advanced aneugenicity and fungal cell mitosis research. This article reveals how recent mechanistic assays inform assay design and compound selection, providing novel insights beyond standard antifungal applications.

• Omeprazole (A2845): Protocols for H+,K+-ATPase Inhibition St

  2026-04-30

  Omeprazole (SKU A2845) is a high-purity H+,K+-ATPase inhibitor, designed for robust gastric acid secretion research and antiulcer activity studies. It should not be used for diagnostic or clinical applications. This compound is best suited for in vitro and preclinical workflows requiring precise control of proton pump inhibition.

• RapaLink-1: Third-Generation mTOR Inhibitor for Dormancy & C

  2026-04-29

  RapaLink-1, a third-generation mTOR inhibitor from APExBIO, uniquely enables both robust cancer pathway inhibition and precise induction of embryonic dormancy in vitro. This article details optimized experimental workflows, advanced applications, and troubleshooting strategies to leverage RapaLink-1 for research in oncology and developmental biology.

• Oseltamivir Acid: Strategic Leverage in Translational Resear

  2026-04-29

  This thought-leadership article dissects the mechanistic and translational impact of Oseltamivir acid, an advanced influenza neuraminidase inhibitor, for researchers navigating infectious disease and oncology pipelines. Bridging species-specific pharmacokinetics, resistance mechanisms, and prodrug activation, we provide actionable guidance and next-generation strategies for maximizing the compound’s value in preclinical models and combination therapies. Unique among product-focused articles, this narrative synthesizes recent findings from humanized mouse studies and comparative metabolism research, setting a new standard for translational scientists seeking robust, reproducible, and future-ready solutions. Key numeric claims and recommendations are transparently sourced.

451 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page